Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization due to sorsby macular dystrophy

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 4, 2013, Pages 444-447

  Kapoor, Kapil G ^a   Bakri, Sophie J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ARTICLE; CASE REPORT; CODON; COLOR VISION DEFECT; DRUSEN; EYE INFLAMMATION; FAMILY HISTORY; HUMAN; HYPERLIPIDEMIA; INTRAOCULAR PRESSURE; MALE; MEDICAL HISTORY; METAMORPHOSIS; MYOPIA; NIGHT BLINDNESS; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA DEGENERATION; SLIT LAMP; SORSBY MACULAR DYSTROPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VISION; VISUAL ACUITY; VISUAL FIELD;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRACHYDACTYLY; CHOROIDAL NEOVASCULARIZATION; COLOBOMA; DEXAMETHASONE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84880553000     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0206     Document Type: Article

References (16)

1. Desco, M.C., Mataix, J., Garcia-Pous, M., Palacios-Pozo, E., and Navea, A. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow up. Retina. 31:475-481, 2011.
2. Spiteri Cornish, K., Williams, G.J., Gavin, M.P., and Imrie, F.R. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy. Eur. J. Ophthalmol. 21:440-445, 2011.
3. Waheeb, S.A., and Showail, M.J. Idiopathic choroidal neovascular membrane in a young female. Oman J. Ophthalmol. 2:133-136, 2009.
4. Rishi, E., Rishi, P., and Mahajan, S. Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy. Indian J. Ophthalmol. 58: 160-162, 2010.
5. Kovach, J.L., Schwartz, S.G., Hickey, M., and Puliafito, C.A. Thirty-two month follow-up of successful treatment of choroidal neovascularization from angioid streaks with intravitreal bevacizumab. Ophthalmic. Surg. Lasers Imaging. 40:77-79, 2009.
6. Prager, F., Michels, S., Geitzenauer, W., and Schmidt-Erfurth, U. Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Bevacizumab). Acta. Ophthalmol. Scand. 85:904-906, 2007.
7. Li, Z., Clarke, M.P., Barker, M.D., and McKie, N. TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights. Expert. Rev. Mol. Med. 7:1-15, 2005
8. Holz, F.G., Haimovici, R., Wagner, D.G., et al. Recurrent choroidal neovascularization after laser photocoagulation in Sorsby's fundus dystrophy. Retina. 14:329-334, 1994.
9. Wong, S.C., Fong, K.C.S., Lee, N., Gregory-Evans, K., and Gregory-Evans, C.Y. Successful photodynamic therapy for subretinal neovascularization due to Sorsby's fundus dystrophy: 1 year follow up. Br. J. Ophthalmol. 87:796-797, 2003.
10. Wilde, C.G., Hawkins, P.R., Coleman, R.T., Levine, W.B., Delegeane, A.M., Okamoto, P.M., Ito, L.Y., Scott, R.W., and Seilhamer, J.J. Cloning and Characterization of human tissue inhibitor of metalloproteinases-3. DNA Cell Biol. 13:711-718, 1994.
11. Peters, A.L., and Greenberg, J. Sorsby's fundus dystrophy. A South African family with a point mutation on the tissue inhibitor of metalloproteinases-3 gene on chromosome Retina. 15:480-485, 1995.
12. Isashkiki, T., Tabata, Y., Kamimura, K., and Ohba, N. Sorsby's fundus dystrophy in two Japanese families with unusual clinical features. Jpn. J. Ophthalmol. 43:472-480, 1999.
13. Lip, P.L., Good, P.A., and Gibson, J.M. Sorsby's fundus dystrophy: a case report of 24 years follow-up with electrodiagnostic tests and indocyanine green angiography. Eye. 13(Pt 1):16-25, 1999.
14. Qi, J.H., Ebrahem, Q., Moore, N., Murphy, G., Claesson-Welsh, L., Bond, M., Baker, A., and Anand-Apte, B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. Apr; 9:407-415, 2003.
15. Moshfeghi, A.A., Rosenfeld, P.J., Puliafito, C.A., Michels, S., Marcus, E.N., Lenchus, J.D., and Venkatraman, A.S. Systemic bevacizumab (Bevacizumab) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 113:2002.e1-12, 2006.
16. Sato, T., Emi, K., Ikeda, T., Bando, H., Sato, S., Morita, S., Oyagi, T., and Sawada, K. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology. 117:512-516, 516.e1-2, 2010